Text this: Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials

 ______      ___     _____      _____    __   _   
|      \\   / _ \\  |  __ \\   |  ___|| | || | || 
|  --  //  / //\ \\ | |  \ ||  | ||__   | '--' || 
|  --  \\ |  ___  ||| |__/ ||  | ||__   | .--. || 
|______// |_||  |_|||_____//   |_____|| |_|| |_|| 
`------`  `-`   `-`  -----`    `-----`  `-`  `-`